newsfilter
← Latest News
PR Newswire·

Halozyme to Report Second Quarter 2026 Financial and Operating Results

  • Halozyme Therapeutics, Inc. will release its second quarter 2026 financial & operating results on Thursday, August 6, 2026, following the close of trading.
  • The company will host a conference call on Thursday, August 6, 2026, at 1:30pm PT/4:30pm ET to discuss the results, with live access available via pre-registration.
  • A live webcast & replay of the call will be accessible through the "Investors" section of Halozyme's corporate website.
  • Halozyme's ENHANZE® drug delivery technology, utilizing the proprietary enzyme rHuPH20, has impacted over one million patient lives across ten commercialized products in more than 100 global markets.
  • ENHANZE® is licensed to major pharmaceutical partners including Roche, Takeda, Pfizer, Janssen, AbbVie, Eli Lilly, Bristol-Myers Squibb, argenx, ViiV Healthcare, Chugai Pharmaceutical, Acumen Pharmaceuticals, Merus N.V., Skye Bioscience, GSK, & Incyte.
  • Halozyme expanded its portfolio by developing partner products using Hypercon™ technology & acquired Surf Bio's polymer-based hyperconcentration technology to reduce injection volumes & enable subcutaneous delivery of highly concentrated biologics.
  • Hypercon™ technology has been licensed to Janssen, Eli Lilly, argenx, Vertex Pharmaceuticals, & Oruka Therapeutics.
  • The company develops, manufactures, & commercializes drug-device combination products using advanced auto-injector technologies & holds proprietary commercial products Hylenex® & XYOSTED®.
  • Halozyme maintains ongoing development programs with Teva Pharmaceuticals & McDermott Laboratories Limited, an affiliate of Viatris Inc.
  • Halozyme is headquartered in San Diego, CA, with offices in Ewing, NJ; Minnetonka, MN; & Boston, MA, while its operations facility is located in Minnetonka.